<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Second-trimester pregnancy termination: Dilation and evacuation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Second-trimester pregnancy termination: Dilation and evacuation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Second-trimester pregnancy termination: Dilation and evacuation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cassing Hammond, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jody Steinauer, MD, MAS, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H441158954"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The most common surgical technique for second-trimester termination in the United States is dilation and evacuation (D&amp;E) [<a href="#rid1">1,2</a>]. Other surgical approaches include a variant of D&amp;E called "intact D&amp;E" and hysterotomy [<a href="#rid3">3</a>]. Hysterotomy is rarely used. These rare situations include when it is unsafe to dilate the cervix or induce labor, when no trained D&amp;E provider is available, or when the patient has severe cervical stenosis or leiomyomas that completely obstruct the cervix and vagina.</p><p>The D&amp;E procedure consists of two components:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preparation</strong> – Dilation of the cervix with osmotic, pharmacologic, and/or mechanical dilators.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure</strong> – Evacuation of the uterus with suction, extraction forceps, and curettage.</p><p></p><p>The D&amp;E procedure is reviewed here. Indications, counseling, cervical preparation, and second trimester induction (medication) abortion are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/90163.html" rel="external">"Second-trimester pregnancy termination: Induction (medication) termination"</a>.)</p><p></p><p class="headingAnchor" id="H441157411"><span class="h1">PREPROCEDURE PREPARATION</span></p><p class="headingAnchor" id="H271050462"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>The role of laboratory testing for hemoglobin or hematocrit, Rh typing (and administration of Rhogam to Rh negative individuals), and chlamydia and/or gonorrhea is described in detail separately. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Alloimmunization prevention'</a>.)</p><p class="headingAnchor" id="H441157417"><span class="h2">Cervical preparation</span><span class="headingEndMark"> — </span>Cervical preparation with osmotic dilators (eg, laminaria japonica, Dilapan-S) and/or pharmacologic agents (eg, <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, <a class="drug drug_general" data-topicid="10263" href="/d/drug information/10263.html" rel="external">mifepristone</a>) is performed prior to a second-trimester surgical abortion and usually occurs on the day of, or the day prior to, the procedure. If further cervical dilation is needed, this is performed with mechanical dilators (eg, Pratt, Hegar) at the beginning of the procedure. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion"</a>.)</p><p class="headingAnchor" id="H441157768"><span class="h2">Injection to induce fetal demise</span><span class="headingEndMark"> — </span>Injection of a substance to cause fetal demise prior to second-trimester surgical abortion is controversial. The advantages of this practice are that feticidal injection precludes the possibility of live birth, thereby potentially reducing emotional stress on the patient, and also allowing the surgeon to minimize concerns regarding compliance with legislation that penalizes uterine evacuation in which portions of the fetus are removed prior to demise [<a href="#rid4">4</a>]. In addition, it has been proposed that fetal demise makes the procedure technically easier by inducing fetal maceration and cervical priming, but this has not been scientifically demonstrated. Many clinicians use such injections before all second-trimester surgical abortions, while others use them only in those cases in which they consider this to have a benefit for the patient.</p><p>The benefits of feticidal injection to the patient remain unproven. Two randomized trials arrived at conflicting results regarding whether injection of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> prior to D&amp;E resulted in an increased rate of extramural birth (spontaneous delivery of the fetus prior to the procedure) or an increased risk of infection [<a href="#rid5">5,6</a>]. Extramural birth sometimes occurs prior to demise, and this, along with the unplanned nature of this event, may potentially cause distress to the patient. In addition, feticidal injection has been associated with an increased rate of nausea or pelvic pain [<a href="#rid4">4</a>]. A report by the Society of Family Planning found insufficient evidence to support pre-D&amp;E feticidal injection [<a href="#rid7">7</a>]. Some experts have questioned the ethics of adding this invasive procedure with potential risks and unproven benefits, particularly if performed principally to fulfill a legal requirement.</p><p>Given the available data and other considerations, for most patients undergoing second-trimester D&amp;E, we suggest <strong>not</strong> using feticidal injection. Use of feticidal injection is a reasonable option for patients who find it emotionally reassuring and who are willing to accept a potential increased risk of extramural birth, infection, and other adverse effects (nausea or pelvic pain).</p><p>The technique and choice of agents used for induced fetal demise are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/6819.html" rel="external">"Induced fetal demise"</a>.)</p><p class="headingAnchor" id="H441157854"><span class="h2">Anesthesia</span><span class="headingEndMark"> — </span>Second-trimester D&amp;E is typically performed using a paracervical block and intravenous conscious sedation. Anesthesia for D&amp;E is discussed separately. </p><p class="headingAnchor" id="H441157872"><span class="h2">Prophylactic antibiotics</span></p><p class="bulletIndent1"><span class="glyph">●</span>In our practice, we administer <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 200 mg orally one hour prior to uterine evacuation. Other providers prefer a single dose of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> 500 mg orally at time of dilator placement. Because of its long half-life, a second dose of azithromycin is only given if the surgical abortion is performed &gt;24 hours after the initial dose of antibiotics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If dilators are <strong>not</strong> used prior to the surgical abortion, various acceptable antibiotic regimens are available  (<a class="graphic graphic_table graphicRef129043" href="/d/graphic/129043.html" rel="external">table 1</a>).</p><p></p><p>A more thorough discussion regarding antibiotic prophylaxis is provided elsewhere. (See  <a class="medical medical_review" href="/d/html/3287.html" rel="external">"First-trimester pregnancy termination: Uterine aspiration", section on 'Antibiotic prophylaxis'</a> and  <a class="medical medical_review" href="/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion", section on 'Procedure'</a>.)</p><p class="headingAnchor" id="H2215038"><span class="h2">Thromboprophylaxis</span><span class="headingEndMark"> — </span>Thromboprophylaxis is not typically required for second-trimester D&amp;E. Indications for thromboprophylaxis for surgical procedures are discussed separately. (See  <a class="medical medical_review" href="/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="headingAnchor" id="H441157935"><span class="h1">PROCEDURE</span></p><p class="headingAnchor" id="H441157941"><span class="h2">Speculum</span><span class="headingEndMark"> — </span>A Graves or Pederson speculum is typically used, but in some cases, these speculums make the D&amp;E procedure challenging to accomplish because they prevent introduction of extraction forceps beyond the hub of the speculum. Alternatives include using a side-open speculum that provides additional space for extraction, doing the procedure without a speculum (using care to visualize the cervix with each pass of the forceps) or using a short-bladed speculum (eg, Klopfer speculum). Our choice of speculum varies depending on the patient's anatomy and body habitus.</p><p class="headingAnchor" id="H441157947"><span class="h2">Cervical dilation</span><span class="headingEndMark"> — </span>Based upon the diameter of most forceps used for D&amp;E, the minimum dilation required ranges from 14 to 19 mm (42 to 57 French) and depends on gestational age [<a href="#rid8">8</a>]. Sufficient cervical dilation decreases the risk of morbidity, including cervical injury and uterine perforation [<a href="#rid9">9-11</a>].</p><p>In general, the extraction forceps should easily traverse the cervix without resistance. In our practice, we use Sopher forceps  (<a class="graphic graphic_picture graphicRef87448" href="/d/graphic/87448.html" rel="external">picture 1</a>) for pregnancies through 16 to 18 weeks' gestational size. After 18 weeks of gestation, we prefer the larger Bierer forceps  (<a class="graphic graphic_picture graphicRef87449" href="/d/graphic/87449.html" rel="external">picture 2</a>).</p><p>The procedure and instrumentation for mechanical cervical dilation is described separately. (See  <a class="medical medical_review" href="/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion", section on 'Role of mechanical dilation'</a>.) </p><p class="headingAnchor" id="H441158031"><span class="h2">Uterine evacuation</span><span class="headingEndMark"> — </span>The D&amp;E procedure for evacuation of the fetus and placenta is performed using a combination of suction, extraction with forceps, and curettage.</p><p>After adequate cervical dilation is achieved, suction curettage is performed. Suction cannulae up to 16 mm permit evacuation of gestations through approximately 16 to 18 weeks. Operators perform suction in later gestations to remove amniotic fluid prior to fetal extraction The procedure for suction curettage is described separately. (See  <a class="medical medical_review" href="/d/html/3287.html" rel="external">"First-trimester pregnancy termination: Uterine aspiration"</a>.)</p><p>If a cannula smaller than 16 mm is used or the gestational age is greater than 16 to 18 weeks, suction curettage is followed by use of fetal extractor forceps (eg, Hern, Van Lith, Sopher, or Bierer forceps) to remove fetal parts  (<a class="graphic graphic_picture graphicRef87448" href="/d/graphic/87448.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef87449" href="/d/graphic/87449.html" rel="external">picture 2</a>). Procedures that require use of large forceps should be performed by an experienced surgeon.</p><p>Techniques that facilitate the procedure and help to avoid complications include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ultrasound guidance can provide information about the uterine anatomy and the location of fetal parts. This may facilitate technically challenging extractions and may decrease the risk of uterine perforation [<a href="#rid12">12</a>]. Providers should consider using ultrasound in patients with obesity or uterine anomalies, when training inexperienced providers, and in any case in which the provider experiences difficulty with evacuation. One study of over 4500 second-trimester surgical abortions found no increased risk of complications in patients with obesity [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Digital examination of the uterine cavity can help to locate fetal parts, which helps to correctly place the extraction forceps.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most surgeons find they have to open the extraction forceps wider than anticipated, particularly to encircle the calvaria of a later gestation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pregnant uterus curves somewhat anteriorly. Some forceps, such as the Hern, angle the jaws of the instrument anteriorly to help correct for the natural location of fetal parts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgeons must be very careful to avoid pushing fetal parts with the forceps since this may push them deeper into the fundus and even through the uterine wall, causing uterine perforation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The fetal parts should be brought down to the lower uterine segment for disarticulation. This prevents operating in close proximity to the thinner and more easily perforated uterine fundus. Caution should be employed since bony spicules exposed during fetal disarticulation can perforate the uterine walls and abrade the cervix.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The optimal approach is to operate in the midline. More lateral placement of forceps may result in a lateral uterine perforation with potential involvement of the uterine vessels.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgeons should attempt to reduce the number of passes of extraction forceps since this reduces the opportunity to perforate the uterus or abrade the cervix. When possible, the fetus should be removed as intact as possible, which minimizes the number of passes and provides greater assurance of complete extraction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgeons may utilize the Hanson maneuver to improve fetal localization [<a href="#rid14">14</a>]. With the extraction forceps placed in the lower uterine cavity, surgeons places their other hand on the patient's abdominal wall to localize the forceps in relation to fetal parts and to help prevent uterine perforation.</p><p></p><p>Both the fetus and placenta must be entirely removed. Some surgeons prefer to remove the placenta after the fetus to avoid disruption of the placental bed, but this is not always possible. The placenta has a characteristic soft consistency that experienced surgeons can discern with extractors.</p><p>Following extraction of fetal and placental tissue, most surgeons finish the D&amp;E by curetting the uterine lining with a suction cannula. This permits removal of most of any remaining placental fragments. Some surgeons then perform a "curette check," using a sharp curette to gently feel for any retained parts and confirm the texture of an empty uterus. In our experience, this maneuver is not necessary and has the potential to needlessly increase pain, as well as the risk of uterine perforation [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H78403710"><span class="h3">Intact dilation and evacuation</span><span class="headingEndMark"> — </span>A variant of D&amp;E is intact D&amp;E. With this technique, the fetus is removed intact or nearly intact through the cervix [<a href="#rid17">17,18</a>]. After achieving sufficient cervical dilation with osmotic dilators, surgeons use extraction forceps to deliver a breech fetus until the calvaria is lodged above the internal os. The remainder of the fetus is delivered intact following decompression of the calvaria, often by suctioning intracranial contents. If the fetus is in vertex presentation, the surgeon can make an incision in the calvaria, suction intracranial contents, and collapse the calvaria with extraction forceps. The remainder of the fetus will subsequently deliver intact.</p><p>The potential advantages of intact D&amp;E compared with standard D&amp;E include:</p><p class="bulletIndent1"><span class="glyph">●</span>The likelihood of uterine perforation and cervical abrasion may be decreased because the technique minimizes the number of instrumental passes and permits direct visualization within the vagina.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Because the fetus is removed intact, it might also permit superior morphologic evaluation to further clarify prenatal diagnosis, although pathologic evaluation can also be performed on non-intact specimens [<a href="#rid19">19</a>].</p><p></p><p>The only study comparing intact D&amp;E with standard D&amp;E was a retrospective study of 383 patients who underwent surgical abortion at ≥20 weeks of gestation [<a href="#rid20">20</a>]. There was no difference in estimated blood loss or operative duration between the intact extraction and disarticulation groups. The overall rate of complications was 5 percent in both groups. Three patients in the D&amp;E group required admission to a surgical intensive care unit (complications included amniotic fluid embolus, sepsis, pulmonary embolus, perforation of hysterotomy scar); however, there were insufficient data to detect a difference in the risk of major complications.</p><p>In the United States, the Partial-Birth Abortion Act of 2003 criminalizes some variants of D&amp;E and provides no legal exception for cases performed to protect maternal health. Clinicians should consult the provisions of the law if they intend to perform an intact extraction, and some experts advise use of preoperative feticidal injection.</p><p class="headingAnchor" id="H441158240"><span class="h2">Use of uterotonics and vasoconstrictive agents</span><span class="headingEndMark"> — </span>The routine use of perioperative or postoperative uterotonic agents (eg, <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a>, <a class="drug drug_general" data-topicid="9637" href="/d/drug information/9637.html" rel="external">methylergonovine</a>, carboprost, <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>) is a subject of debate. Although many providers, including the author of this topic, routinely use uterotonics and vasoconstrictive agents, Society of Family Planning guidelines advise that there is no compelling evidence justifying their routine use [<a href="#rid21">21,22</a>], and in one randomized trial, methylergonovine prophylaxis at the time of D&amp;E increased rates of excess bleeding [<a href="#rid23">23</a>]. The risk of perioperative hemorrhage increases with advancing gestational age and is most commonly the result of uterine atony. The uterus becomes increasingly responsive to oxytocin after 20 weeks of gestation, increasing its efficacy in treating hemorrhage.</p><p>Options for use of prophylactic uterotonic or vasoconstrictive agents include:</p><p class="bulletIndent1"><span class="glyph">●</span>Paracervical injection at the time the paracervical block. Dilute <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> or dilute <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> injected during deep paracervical injection may help control blood loss [<a href="#rid24">24-26</a>]. Paracervical injection of vasopressin was found to significantly reduce blood loss in a randomized trial [<a href="#rid24">24</a>]. In our practice, we use a solution of vasopressin 5 units in 20 mL of 1 percent <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> and administer 10 mL of the solution on each side of the cervix.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In our practice, we administer intravenous <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> at the time of speculum placement for evacuations &gt;18 weeks gestation [<a href="#rid27">27</a>]. Some surgeons initiate uterotonics only after evacuation based on a concern of entrapping fetal material as the uterus contracts.</p><p></p><p class="headingAnchor" id="H441158327"><span class="h2">Assessment for retained products of conception</span><span class="headingEndMark"> — </span>At the end of the procedure, the surgeon should inventory evacuated contents and account for the major fetal parts (calvaria, thorax, pelvis, four extremities). The most important measure of complete evacuation is the clinical assessment of an experienced surgeon who has inspected evacuated products.</p><p>Pelvic ultrasound may also be helpful. This is particularly the case when clinicians evacuate anomalous pregnancies or pregnancies in which fetal demise results in substantial maceration of fetal anatomy. Unfortunately, small blood clots rapidly accumulate immediately after D&amp;E, which may obscure some fetal parts or mimic the appearance of a retained placenta.</p><p class="headingAnchor" id="H441158333"><span class="h1">OUTCOME AND COMPLICATIONS</span><span class="headingEndMark"> — </span>Second-trimester surgical abortion is a safe and effective procedure. Uterine evacuation is completed in a single procedure for most patients. In general, less than 5 percent of patients have retained products of conception or a complication. Complications of D&amp;E, in addition to retained products of conception, include cervical laceration, uterine perforation, infection, and hemorrhage [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H441158365"><span class="h2">Retained products of conception</span><span class="headingEndMark"> — </span>Retained products of conception are found following less than 1 percent of second-trimester D&amp;E procedures [<a href="#rid28">28,29</a>]. The evaluation and management of retained products of conception is discussed separately. (See  <a class="medical medical_review" href="/d/html/5482.html" rel="external">"Retained products of conception in the first half of pregnancy"</a>.)</p><p class="headingAnchor" id="H441158409"><span class="h2">Uterine perforation</span><span class="headingEndMark"> — </span>Uterine perforation is potentially one of the most serious complications of surgical abortion and occurs in less than 1 percent of second-trimester D&amp;E procedures [<a href="#rid9">9,30</a>]. In some cases, a perforation results in hemorrhage or damage to the bowel or bladder or to large vessels. Factors that increase the risk of uterine perforation include increasing gestational age, cervical abnormalities, multiparity, and an inexperienced provider. Perforations in the second trimester are more likely to involve injury to bowel or other structures than those occurring in the first trimester [<a href="#rid10">10,31</a>]. The evaluation and management of uterine perforation is discussed separately. (See  <a class="medical medical_review" href="/d/html/3309.html" rel="external">"Uterine perforation during gynecologic procedures"</a>.)</p><p class="headingAnchor" id="H441158479"><span class="h2">Cervical laceration</span><span class="headingEndMark"> — </span>A cervical laceration occurs in up to 3 percent of second-trimester abortions, whether performed by D&amp;E or medical abortion [<a href="#rid32">32</a>]. Surgeons can reduce the frequency of cervical laceration by using cervical preparation and by appropriate technique with mechanical dilators. (See  <a class="medical medical_review" href="/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion"</a>.)</p><p>Most cervical lacerations are small and require no intervention, provided they remain hemostatic. Treatment options for bleeding lacerations include clamp compression for several minutes, application of <a class="drug drug_general" data-topicid="83319" href="/d/drug information/83319.html" rel="external">ferric subsulfate</a> solution (Monsel solution) or suturing. Cervical lacerations of the internal os, also known as "cervical fractures," can dissect laterally into the paracervical space, causing severe hemorrhage or hematoma formation. Surgeons should suspect high cervical injury when bleeding continues postoperatively despite preservation of normal uterine tone. Application of pressure and ferric subsulfate solution controls many of these injuries. Balloon tamponade and angiographic embolization might also help control bleeding from severe high cervical tears [<a href="#rid33">33</a>]. (See <a class="local">'Cervical preparation'</a> above.)</p><p class="headingAnchor" id="H441158528"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Infection rates following second-trimester abortion vary up to as high as 4 percent. Definitions of postabortion infection vary, as do diagnostic criteria for postabortal endometritis [<a href="#rid9">9,30,34</a>]. Use of prophylactic antibiotics, as recommended above, reduces rates of infection to less than 1 percent [<a href="#rid35">35</a>]. There are no data regarding the rates of infection in surgical abortion compared with medical induction abortion regimens. (See <a class="local">'Prophylactic antibiotics'</a> above.)</p><p>The management of postabortal endometritis is similar to that for postpartum endometritis. (See  <a class="medical medical_review" href="/d/html/5488.html" rel="external">"Postpartum endometritis"</a>.)</p><p class="headingAnchor" id="H441158617"><span class="h2">Hemorrhage</span><span class="headingEndMark"> — </span>Definitions of postabortion hemorrhage vary. Although many investigators have previously defined hemorrhage as an estimated blood loss of ≥200 mL, the Society of Family Planning definition is either ≥500 mL or a surrogate marker (eg, need for transfusion) [<a href="#rid21">21</a>]. Estimates of the incidence of postabortion hemorrhage vary. Rates reported in published series range from 0 to 3 cases/1000 first-trimester procedures versus 0.9 to 10/1000 cases of second-trimester abortion [<a href="#rid21">21</a>]. There are no data regarding the rates of hemorrhage in surgical compared with induction abortion. However, blood loss is higher in induction procedures [<a href="#rid21">21,36,37</a>].</p><p>Hemorrhage can result from a variety of causes, including uterine atony, retained products of conception, coagulopathy, abnormal placentation, and uterine or cervical injury. Uterine atony is the most common cause of hemorrhage following D&amp;E and complicates approximately 2 percent of D&amp;E procedures [<a href="#rid38">38</a>].</p><p>Prior cesarean birth is also associated with an increased risk of postabortion hemorrhage. This increase in risk is seen after one cesarean (1.8 times higher in one study [<a href="#rid13">13</a>]), and notably was 7.4 times higher after two or more cesarean deliveries in another study [<a href="#rid38">38</a>]. Operators confronting patients with a history of prior cesarean should consider taking perioperative measures to reduce the likelihood of hemorrhage, including use of <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> in the paracervical block and utilization of preoperative cervical ripening agents. They should also anticipate hemorrhage by assuring the presence of pharmacologic and other agents necessary to treat postabortion hemorrhage when it arises. (See  <a class="medical medical_review" href="/d/html/6710.html" rel="external">"Overview of postpartum hemorrhage"</a>.)</p><p class="headingAnchor" id="H441158735"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>From 2004 to 2008, the United States Centers for Disease Control and Prevention reported a mortality rate of 0.64 per 100,000 legal induced abortions; these data are for first- and second-trimester abortions, and the majority of abortions were D&amp;E procedures [<a href="#rid39">39</a>]. The strongest risk factor for surgical abortion-related mortality is increasing gestational age. The risk of death from surgical abortion increases roughly 38 percent per week of gestation after eight weeks [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H441160655"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Follow-up for second-trimester D&amp;E, including contraception options and methods to suppress lactation, is the same as for induction (medication) abortion and discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Postprocedure considerations'</a> and  <a class="medical medical_review" href="/d/html/109209.html" rel="external">"Contraception: Postabortion"</a>.)</p><p class="headingAnchor" id="H2214297"><span class="h1">FUTURE OBSTETRIC OUTCOMES</span><span class="headingEndMark"> — </span>Study results vary regarding D&amp;E and risks to subsequent pregnancy. Some studies have found an increased risk of cervical insufficiency with rapid mechanical dilation or an increasing number of abortion procedures [<a href="#rid41">41</a>].</p><p>However, in a retrospective review of 600 patients undergoing D&amp;E between 14 and 24 weeks, the overall rate of preterm birth in subsequent pregnancies was less than the overall rate of preterm birth for the general United States population (6.5 versus 12.5 percent) [<a href="#rid42">42</a>]. Similarly, a study that compared subsequent pregnancy outcomes among 317 patients undergoing second-trimester D&amp;E with 170 matched controls found that patients with a history of prior D&amp;E delivered slightly earlier in gestation than controls (38.9 versus 39.5 weeks of gestation); this was statistically significant, but clinical significance is uncertain. There was no statistically significant difference in birth weight, spontaneous preterm delivery, abnormal placentation, and overall rates of perinatal complications [<a href="#rid43">43</a>]. A recent study demonstrated a higher rate of preterm birth after second-trimester induction abortion compared with D&amp;E [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H441160673"><span class="h1">SPECIAL CIRCUMSTANCES</span><span class="headingEndMark"> — </span>Management of patients with special issues of concern (eg, uterine anomalies, low-lying placenta, multiple gestation, rupture of membranes) is discussed separately. (See  <a class="medical medical_review" href="/d/html/14194.html" rel="external">"Overview of second-trimester pregnancy termination", section on 'Special circumstances'</a>.)</p><p class="headingAnchor" id="H169990229"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109182.html" rel="external">"Society guideline links: Pregnancy termination"</a>.)</p><p class="headingAnchor" id="H441160545"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15750.html" rel="external">"Patient education: Abortion (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/8400.html" rel="external">"Patient education: Abortion (pregnancy termination) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H441159843"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procedure overview</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most common surgical technique for second-trimester termination in the United States is dilation and evacuation (D&amp;E). Other surgical approaches include intact D&amp;E, which is a variant of D&amp;E, and hysterotomy. Hysterotomy is rarely used except when it is unsafe to dilate the cervix or induce labor. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The D&amp;E procedure consists of two components: (1) preparation and dilation of the cervix with osmotic, pharmacologic, and/or mechanical dilators, and (2) evacuation of the uterus with suction, extraction forceps, and curettage. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of preprocedure feticide</strong> – For most patients undergoing second-trimester D&amp;E, we suggest not using preprocedure feticide (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Use of feticidal injection is a reasonable option for patients who place a high value on preprocedure feticidal injection and who are willing to accept a potential increased risk of extramural birth, infection, and other adverse effects (nausea or pelvic pain). (See <a class="local">'Injection to induce fetal demise'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic antibiotics</strong> – To decrease the risk of infection, we give <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> 200 mg orally one hour prior to uterine evacuation. Other providers give <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> 500 mg orally once when dilators are placed. If dilators are <strong>not</strong> used prior to the surgical abortion, various acceptable antibiotic regimens are available  (<a class="graphic graphic_table graphicRef129043" href="/d/graphic/129043.html" rel="external">table 1</a>). (See <a class="local">'Prophylactic antibiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uterine evacuation</strong> <strong>technique</strong> – The D&amp;E procedure for evacuation of the fetus and placenta is performed using a combination of suction, extraction with forceps  (<a class="graphic graphic_picture graphicRef87448" href="/d/graphic/87448.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef87449" href="/d/graphic/87449.html" rel="external">picture 2</a>), and curettage. (See <a class="local">'Uterine evacuation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic uterotonic or vasoconstrictive agents</strong> – The routine use of perioperative or postoperative uterotonic agents (eg, <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a>, <a class="drug drug_general" data-topicid="9637" href="/d/drug information/9637.html" rel="external">methylergonovine</a>) or vasoconstrictive agents is a subject of debate. In our practice, we use a paracervical injection of <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> during our paracervical block with <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> to help control blood loss and administer intravenous oxytocin beginning at the time of speculum placement for all evacuations &gt;18 weeks gestation. (See <a class="local">'Use of uterotonics and vasoconstrictive agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment for retained products</strong> – Surgeons must document completion of D&amp;E by inspecting the products of conception for the four extremities and calvaria. Intraoperative pelvic ultrasound can assist surgeons performing D&amp;E, particularly in a teaching setting. (See <a class="local">'Assessment for retained products of conception'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – In general, fewer than 5 percent of patients who undergo second-trimester D&amp;E have retained products of conception or a complication. Potential complications of second-trimester D&amp;E include retained products of conception, uterine perforation, cervical laceration, infection, and hemorrhage. (See <a class="local">'Outcome and complications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Tietze C, Henshaw SK. Induced abortion: a world review, 3rd ed, Alan Guttmacher Institute, New York 1986.</li><li><a class="nounderline abstract_t">Stubblefield PG, Carr-Ellis S, Borgatta L. Methods for induced abortion. Obstet Gynecol 2004; 104:174.</a></li><li><a class="nounderline abstract_t">Prager SW, Oyer DJ. Second-trimester surgical abortion. Clin Obstet Gynecol 2009; 52:179.</a></li><li><a class="nounderline abstract_t">Grimes DA, Stuart GS, Raymond EG. Feticidal digoxin injection before dilation and evacuation abortion: evidence and ethics. Contraception 2012; 85:140.</a></li><li><a class="nounderline abstract_t">Steward R, Melamed A, Kim R, et al. Infection and extramural delivery with use of digoxin as a feticidal agent. Contraception 2012; 85:150.</a></li><li><a class="nounderline abstract_t">Dean G, Colarossi L, Lunde B, et al. Safety of digoxin for fetal demise before second-trimester abortion by dilation and evacuation. Contraception 2012; 85:144.</a></li><li><a class="nounderline abstract_t">Diedrich J, Drey E, Society of Family Planning. Induction of fetal demise before abortion. Contraception 2010; 81:462.</a></li><li><a class="nounderline abstract_t">Fox MC, Hayes JL, Society of Family Planning. Cervical preparation for second-trimester surgical abortion prior to 20 weeks of gestation. Contraception 2007; 76:486.</a></li><li><a class="nounderline abstract_t">Peterson WF, Berry FN, Grace MR, Gulbranson CL. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol 1983; 62:185.</a></li><li><a class="nounderline abstract_t">Grimes DA, Schulz KF, Cates WJ Jr. Prevention of uterine perforation during curettage abortion. JAMA 1984; 251:2108.</a></li><li><a class="nounderline abstract_t">Schulz KF, Grimes DA, Cates W Jr. Measures to prevent cervical injury during suction curettage abortion. Lancet 1983; 1:1182.</a></li><li><a class="nounderline abstract_t">Darney PD, Sweet RL. Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation. J Ultrasound Med 1989; 8:71.</a></li><li><a class="nounderline abstract_t">Lederle L, Steinauer JE, Montgomery A, et al. Obesity as a Risk Factor for Complications After Second-Trimester Abortion by Dilation and Evacuation. Obstet Gynecol 2015; 126:585.</a></li><li class="breakAll">Hammond C, Chasen S. Dilation and evacuation. In: Management of unintended and abnormal pregnancy: Comprehensive abortion care, Paul M, Lichtenberg S, Borgatta L, et al (Eds), Wiley-Blackwell, Oxford 2003. p.167.</li><li><a class="nounderline abstract_t">Forna F, Gülmezoglu AM. Surgical procedures to evacuate incomplete abortion. Cochrane Database Syst Rev 2001; :CD001993.</a></li><li><a class="nounderline abstract_t">Lindell G, Flam F. Management of uterine perforations in connection with legal abortions. Acta Obstet Gynecol Scand 1995; 74:373.</a></li><li class="breakAll">McMahon JT. Intact D&amp;E. The first decade. Presented at the National Abortion Federation conference. April, 1995.</li><li class="breakAll">Haskell M. Dilation and extraction for late second trimester abortion. Presented at the National Abortion Federation Risk Management Seminar. September 1992.</li><li><a class="nounderline abstract_t">Gawron LM, Hammond C, Ernst LM. Perinatal pathologic examination of nonintact, second-trimester fetal demise specimens: the value of standardization. Arch Pathol Lab Med 2013; 137:1083.</a></li><li><a class="nounderline abstract_t">Chasen ST, Kalish RB, Gupta M, et al. Dilation and evacuation at &gt;or=20 weeks: comparison of operative techniques. Am J Obstet Gynecol 2004; 190:1180.</a></li><li><a class="nounderline abstract_t">Kerns J, Steinauer J. Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131. Contraception 2013; 87:331.</a></li><li><a class="nounderline abstract_t">O'Connell K, Jones HE, Lichtenberg ES, Paul M. Second-trimester surgical abortion practices: a survey of National Abortion Federation members. Contraception 2008; 78:492.</a></li><li><a class="nounderline abstract_t">Kerns JL, Pearlson G, Mengesha B, et al. A randomized controlled trial of methylergonovine prophylaxis after dilation and evacuation abortion. Contraception 2021; 103:116.</a></li><li><a class="nounderline abstract_t">Schulz KF, Grimes DA, Christensen DD. Vasopressin reduces blood loss from second-trimester dilatation and evacuation abortion. Lancet 1985; 2:353.</a></li><li class="breakAll">Glick E. Surgical abortion, West End Women's Medical Group, 1998.</li><li><a class="nounderline abstract_t">Fairchild K, Altinok M, Kram JJF, et al. Using Prophylactic Antihemorrhagic Medications in Second-Trimester Surgical Abortions. Obstet Gynecol 2022; 140:663.</a></li><li><a class="nounderline abstract_t">Whitehouse K, Tschann M, Soon R, et al. Effects of Prophylactic Oxytocin on Bleeding Outcomes in Women Undergoing Dilation and Evacuation: A Randomized Controlled Trial. Obstet Gynecol 2019; 133:484.</a></li><li><a class="nounderline abstract_t">Bryant AG, Grimes DA, Garrett JM, Stuart GS. Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation. Obstet Gynecol 2011; 117:788.</a></li><li><a class="nounderline abstract_t">Whitley KA, Trinchere K, Prutsman W, et al. Midtrimester dilation and evacuation versus prostaglandin induction: a comparison of composite outcomes. Am J Obstet Gynecol 2011; 205:386.e1.</a></li><li><a class="nounderline abstract_t">Jacot FR, Poulin C, Bilodeau AP, et al. A five-year experience with second-trimester induced abortions: no increase in complication rate as compared to the first trimester. Am J Obstet Gynecol 1993; 168:633.</a></li><li><a class="nounderline abstract_t">Pridmore BR, Chambers DG. Uterine perforation during surgical abortion: a review of diagnosis, management and prevention. Aust N Z J Obstet Gynaecol 1999; 39:349.</a></li><li><a class="nounderline abstract_t">Autry AM, Hayes EC, Jacobson GF, Kirby RS. A comparison of medical induction and dilation and evacuation for second-trimester abortion. Am J Obstet Gynecol 2002; 187:393.</a></li><li><a class="nounderline abstract_t">Kauff ND, Chelmow D, Kawada CY. Intractable bleeding managed with Foley catheter tamponade after dilation and evacuation. Am J Obstet Gynecol 1995; 173:957.</a></li><li><a class="nounderline abstract_t">Altman AM, Stubblefield PG, Schlam JF, et al. Midtrimester abortion with Laminaria and vacuum evacuation on a teaching service. J Reprod Med 1985; 30:601.</a></li><li><a class="nounderline abstract_t">Sawaya GF, Grady D, Kerlikowske K, Grimes DA. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol 1996; 87:884.</a></li><li><a class="nounderline abstract_t">Niinimäki M, Suhonen S, Mentula M, et al. Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study. BMJ 2011; 342:d2111.</a></li><li><a class="nounderline abstract_t">Thonneau P, Poirel H, Fougeyrollas B, et al. A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration. Hum Reprod 1995; 10:1512.</a></li><li><a class="nounderline abstract_t">Frick AC, Drey EA, Diedrich JT, Steinauer JE. Effect of prior cesarean delivery on risk of second-trimester surgical abortion complications. Obstet Gynecol 2010; 115:760.</a></li><li><a class="nounderline abstract_t">Pazol K, Creanga AA, Zane SB, et al. Abortion surveillance--United States, 2009. MMWR Surveill Summ 2012; 61:1.</a></li><li><a class="nounderline abstract_t">Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol 2004; 103:729.</a></li><li><a class="nounderline abstract_t">Johnstone FD, Beard RJ, Boyd IE, McCarthy TG. Cervical diameter after suction termination of pregnancy. Br Med J 1976; 1:68.</a></li><li><a class="nounderline abstract_t">Kalish RB, Chasen ST, Rosenzweig LB, et al. Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome. Am J Obstet Gynecol 2002; 187:882.</a></li><li><a class="nounderline abstract_t">Jackson JE, Grobman WA, Haney E, Casele H. Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications. Int J Gynaecol Obstet 2007; 96:12.</a></li><li><a class="nounderline abstract_t">Little SE, Janiak E, Bartz D, Smith NA. Second trimester dilation and evacuation: a risk factor for preterm birth? J Perinatol 2015; 35:1006.</a></li></ol></div><div id="topicVersionRevision">Topic 104595 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tietze C, Henshaw SK. Induced abortion: a world review, 3rd ed, Alan Guttmacher Institute, New York 1986.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229018" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Methods for induced abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19407524" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Second-trimester surgical abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067810" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Feticidal digoxin injection before dilation and evacuation abortion: evidence and ethics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067811" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infection and extramural delivery with use of digoxin as a feticidal agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067788" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Safety of digoxin for fetal demise before second-trimester abortion by dilation and evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20472112" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Induction of fetal demise before abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061709" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cervical preparation for second-trimester surgical abortion prior to 20 weeks of gestation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6866362" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6708260" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevention of uterine perforation during curettage abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6133988" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Measures to prevent cervical injury during suction curettage abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2651693" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26244536" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Obesity as a Risk Factor for Complications After Second-Trimester Abortion by Dilation and Evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26244536" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Obesity as a Risk Factor for Complications After Second-Trimester Abortion by Dilation and Evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279744" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Surgical procedures to evacuate incomplete abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7778431" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Management of uterine perforations in connection with legal abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7778431" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Management of uterine perforations in connection with legal abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7778431" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Management of uterine perforations in connection with legal abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899064" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Perinatal pathologic examination of nonintact, second-trimester fetal demise specimens: the value of standardization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167815" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dilation and evacuation at&gt;or=20 weeks: comparison of operative techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218863" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19014796" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Second-trimester surgical abortion practices: a survey of National Abortion Federation members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33075332" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A randomized controlled trial of methylergonovine prophylaxis after dilation and evacuation abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2862514" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vasopressin reduces blood loss from second-trimester dilatation and evacuation abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2862514" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vasopressin reduces blood loss from second-trimester dilatation and evacuation abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36075063" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Using Prophylactic Antihemorrhagic Medications in Second-Trimester Surgical Abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30741801" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effects of Prophylactic Oxytocin on Bleeding Outcomes in Women Undergoing Dilation and Evacuation: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422848" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22083061" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Midtrimester dilation and evacuation versus prostaglandin induction: a comparison of composite outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8438943" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A five-year experience with second-trimester induced abortions: no increase in complication rate as compared to the first trimester.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10554950" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Uterine perforation during surgical abortion: a review of diagnosis, management and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12193931" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A comparison of medical induction and dilation and evacuation for second-trimester abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573279" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intractable bleeding managed with Foley catheter tamponade after dilation and evacuation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4045833" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Midtrimester abortion with Laminaria and vacuum evacuation on a teaching service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8677129" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21508042" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of rates of adverse events in adolescent and adult women undergoing medical abortion: population register based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593526" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A comparative analysis of fall in haemoglobin following abortions conducted by mifepristone (600 mg) and vacuum aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308836" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of prior cesarean delivery on risk of second-trimester surgical abortion complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169413" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Abortion surveillance--United States, 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15051566" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk factors for legal induced abortion-related mortality in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1244938" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cervical diameter after suction termination of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12388969" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17196205" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26491851" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Second trimester dilation and evacuation: a risk factor for preterm birth?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
